Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_assertion type Assertion NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_head.
- NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_provenance.
- NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_assertion evidence source_evidence_literature NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_provenance.
- NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_assertion SIO_000772 23243017 NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_provenance.
- NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_assertion wasDerivedFrom befree-20140225 NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_provenance.
- NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_assertion wasGeneratedBy ECO_0000203 NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_provenance.